Retrospective study on the safety and efficacy of pyrotinib in the treatment of HER2positive non-breast advanced solid tumors.

被引：0
|
作者：
Wang, Jianzheng
Zhang, Baiwen
Cheng, Xiaojiao
Li, Qingli
Lv, Huifang
Nie, Caiyun
Chen, Beibei
Xu, Weifeng
Zhao, Jing
He, Yunduan
Tu, Shuiping
Chen, Xiaobing
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Dept Gastrointestinal Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China
[3] Zheng zhou Univ, Henan Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15064
引用
收藏
页数：1
相关论文
共 50 条
  • [11] The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: A multicenter study
    Gao, Min
    Fu, Chao
    Li, Shanshan
    Chen, Fang
    Yang, Yongteng
    Wang, Chunjian
    Qin, Jie
    Liu, Shuaishuai
    Zhang, Ranran
    Wang, Changyuan
    Zong, Jinbao
    Meng, Liping
    Meng, Xiangjiao
    CANCER MEDICINE, 2022, 11 (03): : 735 - 742
  • [12] Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study
    Dai, Lanyi
    Gao, Ting
    Guo, Rong
    Chen, Yuyuan
    Wang, Jiankui
    Zhou, Shaoqiang
    Tang, Yiyin
    Chen, Dedian
    Huang, Sheng
    NEOPLASIA, 2024, 56
  • [13] The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
    Li, Fu
    Liang, Yimin
    Luo, Ming
    Shen, Jiayue
    Zhou, Taosheng
    Liang, Yajing
    Tang, Xiaoqi
    Yuan, Huiming
    Zeng, Jian
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [14] Efficacy and safety of pyrotinib-based therapy in HER2-positive metastatic colorectal and gastric cancer: A retrospective study
    Li, Q.
    Liu, T.
    Cui, Y-H.
    Xu, X. J.
    Xu, B.
    Wang, Y.
    Li, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S558 - S558
  • [15] Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2 positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial.
    Liu, Dan
    Xu, Yingying
    Gong, Jifang
    Yang, Fen
    Shen, Lin
    Li, Huajun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [16] Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2-positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial.
    Liu, Dan
    Gong, Jifang
    Xu, Yingying
    Yang, Fen
    Li, Huajun
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 368 - 368
  • [17] Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
    Li, Yan
    Ma, Xiaoping
    Zhao, Zhenhui
    Li, Li
    Gao, Chunyan
    Liu, Dan
    Li, Bingyu
    Zhao, Bing
    BREAST CANCER-TARGETS AND THERAPY, 2022, 14 : 405 - 415
  • [18] Pyrotinib in the treatment of women with advanced HER2 positive breast cancer: A multicenter, prospective, real world study
    Feng, Jifeng
    Zhang, Lili
    Guo, Zhaoji
    Zhou, Jun
    Zhu, Mingzhen
    Wu, Xiaohong
    Yi, Tongbo
    Guo, Yujiang
    Li, Xiaoqin
    Yu, Hao
    Mao, Weidong
    Gu, Bei
    Han, Zhengxiang
    Zuo, Yun
    Liu, Yanhua
    Wang, Xufen
    CANCER RESEARCH, 2021, 81 (04)
  • [19] EFFICACY AND SAFETY OF TRASTUZUMAB IN SMALL HER2 POSITIVE TUMORS. A SINGLE INSTITUTION EXPERIENCE
    Sano, M. V.
    Taibi, E.
    Ali, M.
    Chiarenza, M.
    Clementi, S.
    Caruso, M.
    Aiello, R. A.
    ANNALS OF ONCOLOGY, 2012, 23 : 104 - 104
  • [20] Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
    Li, Yi
    Qiu, Yixuan
    Li, Huihui
    Luo, Ting
    Li, Wei
    Wang, Hong
    Shao, Bin
    Wang, Biyun
    Ge, Rui
    FRONTIERS IN ONCOLOGY, 2021, 11
12345